Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism ACE inhibitors(Angiotensin-converting enzyme inhibitors), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS Registry344423-98-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyslipidemias | Phase 1 | UA | 09 Sep 2021 | |
Hypertension | Phase 1 | GE | 09 Sep 2021 | |
Hypertension | Phase 1 | RU | 09 Sep 2021 | |
Hypertension | Phase 1 | UA | 09 Sep 2021 | |
Dyslipidemias | Preclinical | GE | 09 Sep 2021 | |
Dyslipidemias | Preclinical | RU | 09 Sep 2021 | |
Hyperlipidemias | Discovery | FR | - | 23 Nov 2020 |